PBS listing changes effective 1 May 2025
21 May 2025
Update
Services Australia have announced recent changes to Pharmaceutical Benefits Scheme (PBS) effective from 1 May 2025. This includes listings relevant to psychiatric practice reprinted below:
- Schizophrenia
Aripiprazole (720 mg/2.4 mL modified release injection, 2.4mL syringe; 960 mg/3.2 mL modified release injection, 3.2mL syringe; (Abilify Asimtufii®) is now listed on the PBS for the treatment of schizophrenia. Prescriptions for treatment are Authority required (STREAMLINED). - Treatment resistant major depression
Esketamine (28 mg/2 actuations nasal spray, 2 actuations; 28 mg/2 actuations nasal spray, 2 x 2 actuations; 28 mg/2 actuations nasal spray, 3 x 2 actuations) (Spravato®) is now listed on the PBS for the treatment of treatment resistant major depression. Authority applications for initial (induction), grandfather and continuing (non-induction) treatments can be made either in real-time using the Online PBS Authorities system of by telephone.
Further details about these and other listing changes are available via the PBS website.
More news & views

From the President September 2025
Comprehensive consultation to inform the next RANZCP Strategic Plan 2026–30 has commenced. This is a...
25 September 2025
RANZCP 2026-2030 Strategic Plan: have your say
Have your say on the direction of the College through to 2030 and beyond.
24 September 2025
RANZCP Innovate Reconciliation Action Plan progress update (September 2025)
As of 20 September, 28 of this year’s deliverables have been completed, and the mandatory annual rep...